• François Angoulvant, Xavier Bellêttre, Karen Milcent, Jean-Paul Teglas, Isabelle Claudet, Christèle Gras Le Guen, Loïc de Pontual, Philippe Minodier, François Dubos, Jacques Brouard, Valérie Soussan-Banini, Vanessa Degas-Bussiere, Amélie Gatin, Cyril Schweitzer, Ralph Epaud, Amélie Ryckewaert, Pierrick Cros, Yves Marot, Philippe Flahaut, Pascal Saunier, Philippe Babe, Géraldine Patteau, Mathilde Delebarre, Luigi Titomanlio, Bénédicte Vrignaud, Thanh-Van Trieu, Abdelilah Tahir, Delphine Regnard, Pascale Micheau, Oussama Charara, Simon Henry, Dominique Ploin, Henri Panjo, Astrid Vabret, Jean Bouyer, Vincent Gajdos, and Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE) Study Group.
• Service d'accueil des urgences pédiatriques, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
• JAMA Pediatr. 2017 Aug 7; 171 (8): e171333.

ImportanceAcute bronchiolitis is the leading cause of hospitalization among infants. Previous studies, underpowered to examine hospital admission, have found a limited benefit of nebulized hypertonic saline (HS) treatment in the pediatric emergency department (ED).ObjectiveTo examine whether HS nebulization treatment would decrease the hospital admission rate among infants with a first episode of acute bronchiolitis.Design, Setting, And ParticipantsThe Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE) study was a multicenter, double-blind randomized clinical trial on 2 parallel groups conducted during 2 bronchiolitis seasons (October through March) from October 15, 2012, through April 15, 2014, at 24 French pediatric EDs. Among the 2445 infants (6 weeks to 12 months of age) assessed for inclusion, 777 with a first episode of acute bronchiolitis with respiratory distress and no chronic medical condition were included.InterventionsTwo 20-minute nebulization treatments of 4 mL of HS, 3%, or 4 mL of normal saline (NS), 0.9%, given 20 minutes apart.Main Outcomes And MeasuresHospital admission rate in the 24 hours after enrollment.ResultsOf the 777 infants included in the study (median age, 3 months; interquartile range, 2-5 months; 468 [60.2%] male), 385 (49.5%) were randomized to the HS group and 387 (49.8%) to the NS group (5 patients did not receive treatment). By 24 hours, 185 of 385 infants (48.1%) in the HS group were admitted compared with 202 of 387 infants (52.2%) in the NS group. The risk difference for hospitalizations was not significant according to the mixed-effects regression model (adjusted risk difference, -3.2%; 95% CI, -8.7% to 2.2%; P = .25). The mean (SD) Respiratory Distress Assessment Instrument score improvement was greater in the HS group (-3.1 [3.2]) than in the NS group (-2.4 [3.3]) (adjusted difference, -0.7; 95% CI, -1.2 to -0.2; P = .006) and similarly for the Respiratory Assessment Change Score. Mild adverse events, such as worsening of cough, occurred more frequently among children in the HS group (35 of 392 [8.9%]) than among those in the NS group (15 of 384 [3.9%]) (risk difference, 5.0%; 95% CI, 1.6%-8.4%; P = .005), with no serious adverse events.Conclusions And RelevanceNebulized HS treatment did not significantly reduce the rate of hospital admissions among infants with a first episode of acute moderate to severe bronchiolitis who were admitted to the pediatric ED relative to NS, but mild adverse events were more frequent in the HS group.Trial Registrationclinicaltrials.gov Identifier: NCT01777347.

23 keywords...

hide…